



Formulary changes effective 12/13/24

Pharmacy Benefit Additions (Exchange only):

- **Xolremdi (mavorixafor)** – Pharmacy benefit, Non-Preferred brand, PA
- **Rextovy (naloxone)** – Pharmacy benefit, Non-Preferred brand
- **Dyclopro (dyclonine)** – Pharmacy benefit, Non-Formulary
- **Libervant (diazepam)** – Pharmacy benefit, Non-Preferred brand, QL 10 per 30 days
- **Ingrezza (valbenazine)** (Sprinkle capsule) – Pharmacy benefit, Non-Preferred brand, PA
- **Entresto (sacubitril/valsartan)** (Sprinkle capsule) – Pharmacy benefit, Non-Preferred brand
- **Vijoice (alpelisib)** (oral granules) – Pharmacy benefit, Non-Preferred brand, PA, QL 1 per day

Pharmacy Benefit Changes (Exchange only):

- **Xhance (fluticasone propionate)** – Pharmacy benefit, New indication, chronic rhinosinusitis without nasal polyps
- **Otezla (apremilast)** – Pharmacy benefit, Age update.
- **Kevzara (sarilumab)** – Pharmacy benefit, New indications, Polyarticular Juvenile Idiopathic Arthritis (PJIA) and Polymyalgia Rheumatica (PMR)
- **Augtyro (repotrectinib)**– Pharmacy benefit, New indication, Solid Tumors

Medical Benefit Additions/Changes (Medicare and Exchange):

- **Piasky** – Medical benefit, PA, ST
- **Pemgarda** – Medical benefit
- **Nypozi** – Medical benefit, PA, ST